Stratagem IPM client Blue Earth Diagnostics Ltd is acquired by Bracco Imaging

We have been working to support our prostate imaging client, Blue Earth Diagnostics (BED), in what has culminated in a successful acquisition by Italy based Bracco Imaging for a sum in the region of $450 million.  The intellectual property was an important part of this acquisition and we are thrilled to have been a part of this.

Fulvio Renoldi Bracco, CEO of Bracco Imaging stated that “Blue Earth Diagnostics’ innovative products and pipeline will significantly enhance Bracco Imaging’s portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties”. It has been confirmed that the well- established brand name of Blue Earth Diagnostics will be retained with Bracco expressing that “We are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise.”

BED’s first commercialised product, Axumin (fluciclovine F 18) injection is a novel molecular imaging agent approved in the US and the EU for use in PET imaging for men with suspected recurrent prostate cancer.

In April 2018, the company expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer.

We look forward to working with Bracco/BED as they embark on this new phase.